Critical roles of (pro)renin receptor-bound prorenin in diabetes and hypertension

sallies into therapeutic approach

Atsuhiro Ichihara, Hiroshi Itoh, Tadashi Inagami

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

High plasma prorenin levels in diabetic patients predict microvascular complications, but the mechanism of the connection between them has remained unclear. (Pro)renin receptors were recently found in the human kidney, and their distribution in various organs, including the heart, has been identified. Binding of prorenin to the (pro)renin receptor triggers two major pathways: the angiotensin II-dependent pathway as a result of conversion of prorenin to the active form of prorenin by a conformational change, and the angiotensin II-independent intracellular pathway via the (pro)renin receptor. To investigate whether the (pro)renin-receptor-dependent pathways contribute to the pathophysiology of the end-organ damage that occurs in diabetes and hypertension, a (pro)renin receptor blocker (PRRB), which binds to the receptor and competitively inhibits prorenin binding to the receptor, was administered to rats with streptozotocin-induced diabetes and to stroke-prone spontaneously hypertensive rats. PRRB significantly inhibited the development and progression of end-organ damage in these animal models of diabetes and hypertension, and it was of greater benefit than conventional inhibitors in relation to the renin-angiotensin system in diabetic angiotensin II-type 1a-receptor-deficient mice. The (pro)renin receptor may prove useful as an important therapeutic target for the prevention and regression of end-organ damage in diabetes and hypertension.

Original languageEnglish
Pages (from-to)15-19
Number of pages5
JournalJournal of the American Society of Hypertension
Volume2
Issue number1
DOIs
Publication statusPublished - 2008 Jan

Fingerprint

Renin
Hypertension
Therapeutics
Angiotensin II
prorenin receptor
Angiotensin Type 1 Receptor
Experimental Diabetes Mellitus
Inbred SHR Rats
Renin-Angiotensin System
Animal Models
Stroke
Kidney

Keywords

  • Angiotensin
  • cardiac fibrosis
  • mitogen-activated protein kinases
  • nephropathy

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Internal Medicine

Cite this

Critical roles of (pro)renin receptor-bound prorenin in diabetes and hypertension : sallies into therapeutic approach. / Ichihara, Atsuhiro; Itoh, Hiroshi; Inagami, Tadashi.

In: Journal of the American Society of Hypertension, Vol. 2, No. 1, 01.2008, p. 15-19.

Research output: Contribution to journalArticle

@article{9a933c20f1734f93a527e3c1721af22d,
title = "Critical roles of (pro)renin receptor-bound prorenin in diabetes and hypertension: sallies into therapeutic approach",
abstract = "High plasma prorenin levels in diabetic patients predict microvascular complications, but the mechanism of the connection between them has remained unclear. (Pro)renin receptors were recently found in the human kidney, and their distribution in various organs, including the heart, has been identified. Binding of prorenin to the (pro)renin receptor triggers two major pathways: the angiotensin II-dependent pathway as a result of conversion of prorenin to the active form of prorenin by a conformational change, and the angiotensin II-independent intracellular pathway via the (pro)renin receptor. To investigate whether the (pro)renin-receptor-dependent pathways contribute to the pathophysiology of the end-organ damage that occurs in diabetes and hypertension, a (pro)renin receptor blocker (PRRB), which binds to the receptor and competitively inhibits prorenin binding to the receptor, was administered to rats with streptozotocin-induced diabetes and to stroke-prone spontaneously hypertensive rats. PRRB significantly inhibited the development and progression of end-organ damage in these animal models of diabetes and hypertension, and it was of greater benefit than conventional inhibitors in relation to the renin-angiotensin system in diabetic angiotensin II-type 1a-receptor-deficient mice. The (pro)renin receptor may prove useful as an important therapeutic target for the prevention and regression of end-organ damage in diabetes and hypertension.",
keywords = "Angiotensin, cardiac fibrosis, mitogen-activated protein kinases, nephropathy",
author = "Atsuhiro Ichihara and Hiroshi Itoh and Tadashi Inagami",
year = "2008",
month = "1",
doi = "10.1016/j.jash.2007.08.001",
language = "English",
volume = "2",
pages = "15--19",
journal = "Journal of the American Society of Hypertension",
issn = "1933-1711",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

TY - JOUR

T1 - Critical roles of (pro)renin receptor-bound prorenin in diabetes and hypertension

T2 - sallies into therapeutic approach

AU - Ichihara, Atsuhiro

AU - Itoh, Hiroshi

AU - Inagami, Tadashi

PY - 2008/1

Y1 - 2008/1

N2 - High plasma prorenin levels in diabetic patients predict microvascular complications, but the mechanism of the connection between them has remained unclear. (Pro)renin receptors were recently found in the human kidney, and their distribution in various organs, including the heart, has been identified. Binding of prorenin to the (pro)renin receptor triggers two major pathways: the angiotensin II-dependent pathway as a result of conversion of prorenin to the active form of prorenin by a conformational change, and the angiotensin II-independent intracellular pathway via the (pro)renin receptor. To investigate whether the (pro)renin-receptor-dependent pathways contribute to the pathophysiology of the end-organ damage that occurs in diabetes and hypertension, a (pro)renin receptor blocker (PRRB), which binds to the receptor and competitively inhibits prorenin binding to the receptor, was administered to rats with streptozotocin-induced diabetes and to stroke-prone spontaneously hypertensive rats. PRRB significantly inhibited the development and progression of end-organ damage in these animal models of diabetes and hypertension, and it was of greater benefit than conventional inhibitors in relation to the renin-angiotensin system in diabetic angiotensin II-type 1a-receptor-deficient mice. The (pro)renin receptor may prove useful as an important therapeutic target for the prevention and regression of end-organ damage in diabetes and hypertension.

AB - High plasma prorenin levels in diabetic patients predict microvascular complications, but the mechanism of the connection between them has remained unclear. (Pro)renin receptors were recently found in the human kidney, and their distribution in various organs, including the heart, has been identified. Binding of prorenin to the (pro)renin receptor triggers two major pathways: the angiotensin II-dependent pathway as a result of conversion of prorenin to the active form of prorenin by a conformational change, and the angiotensin II-independent intracellular pathway via the (pro)renin receptor. To investigate whether the (pro)renin-receptor-dependent pathways contribute to the pathophysiology of the end-organ damage that occurs in diabetes and hypertension, a (pro)renin receptor blocker (PRRB), which binds to the receptor and competitively inhibits prorenin binding to the receptor, was administered to rats with streptozotocin-induced diabetes and to stroke-prone spontaneously hypertensive rats. PRRB significantly inhibited the development and progression of end-organ damage in these animal models of diabetes and hypertension, and it was of greater benefit than conventional inhibitors in relation to the renin-angiotensin system in diabetic angiotensin II-type 1a-receptor-deficient mice. The (pro)renin receptor may prove useful as an important therapeutic target for the prevention and regression of end-organ damage in diabetes and hypertension.

KW - Angiotensin

KW - cardiac fibrosis

KW - mitogen-activated protein kinases

KW - nephropathy

UR - http://www.scopus.com/inward/record.url?scp=38149029157&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38149029157&partnerID=8YFLogxK

U2 - 10.1016/j.jash.2007.08.001

DO - 10.1016/j.jash.2007.08.001

M3 - Article

VL - 2

SP - 15

EP - 19

JO - Journal of the American Society of Hypertension

JF - Journal of the American Society of Hypertension

SN - 1933-1711

IS - 1

ER -